Interferons as inducers of apoptosis in malignant cells

Journal of Interferon and Cytokine Research

Volumn 33, Issue 4, 2013, Pages 162-170

  Kotredes, Kevin P ^a   Gamero, Ana M ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BORTEZOMIB; FAM14C PROTEIN; FAM14D PROTEIN; IFIT2 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSITOL HEXAKISPHOSPHATE KINASE 2; INTERFERON; NEDD8 ULTIMATE BUSTER 1; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN KINASE; PROTEIN KINASE B; RECOMBINANT ALPHA INTERFERON; STAT1 PROTEIN; STAT2 PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; ENDOTHELIUM CELL; HAIRY CELL LEUKEMIA; HUMAN; INTRACELLULAR SIGNALING; LYMPHOMA; MELANOMA; MYELOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INTERFERONS; MICE; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84876155338     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0110     Document Type: Review

References (96)

1. Abou-Merhi R, Khoriaty R, Arnoult D, El Hajj H, Dbouk H, Munier S, El-Sabban ME, Hermine O, Gessain A, de The H, Mahieux R, Bazarbachi A. 2007. PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells. Leukemia 21(8):1792-1801.
2. Amato RJ. 2005. Renal cell carcinoma: review of novel singleagent therapeutics and combination regimens. Ann Oncol 16(1):7-15.
3. Arulampalam V, Kolosenko I, Hjortsberg L, Bjorklund AC, GranderD, TammKP. 2011. Activation of STAT1 is required for interferon-alpha-mediated cell death. Exp Cell Res 317(1):9-19.
4. Ascierto PA, Gogas HJ, Grob JJ, Algarra SM, Mohr P, Hansson J, Hauschild A. 2012. Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review. Crit Rev Oncol Hematol. [Epub ahead of print]. DOI is: 10.1016/J.critrevonc.2012.07.004
5. Bani MR, Nicoletti MI, Alkharouf NW, Ghilardi C, Petersen D, Erba E, Sausville EA, Liu ET, Giavazzi R. 2004. Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther 3(2):111-121.
6. Barthson J, Germano CM, Moore F, Maida A, Drucker DJ, Marchetti P, Gysemans C, Mathieu C, Nunez G, Jurisicova A, Eizirik DL, Gurzov EN. 2011. Cytokines tumor necrosis factoralpha and interferon-gamma induce pancreatic beta-cell apoptosis through STAT1-mediated Bim protein activation. J Biol Chem 286(45):39632-39643.
7. Chakraborty A, Koldobskiy MA, Sixt KM, Juluri KR, Mustafa AK, Snowman AM, van Rossum DB, Patterson RL, Snyder SH. 2008. HSP90 regulates cell survival via inositol hexakisphosphate kinase-2. Proc Natl Acad Sci U S A 105(4):1134- 1139.
8. Chawla-Sarkar M, Leaman DW, Borden EC. 2001. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 7(6):1821-1831.
9. Chen IF, Ou-Yang F, Hung JY, Liu JC, Wang H, Wang SC, Hou MF, Hortobagyi GN, Hung MC. 2006. AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model. Mol Cancer Ther 5(1):1-7.
10. Cheon H, Stark GR. 2009. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci U S A 106(23):9373-9378.
11. Cheon H, Yang J, Stark GR. 2011. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine- inducible proteins. J Interferon Cytokine Res 31(1):33-40.
12. Cheriyath V, Glaser KB, Waring JF, Baz R, Hussein MA, Borden EC. 2007. G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J Clin Invest 117(10):3107-3117.
13. Cheriyath V, Leaman DW, Borden EC. 2011. Emerging roles of FAM14 family members (G1P3/ISG 6-16 and ISG12/IFI27) in innate immunity and cancer. J Interferon Cytokine Res 31(1):173-181.
14. Chim CS. 2010. Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/ thalidomide/ dexamethasone in transplant eligible patients. J Transl Med 8:124.
15. Choubey D, Duan X, Dickerson E, Ponomareva L, Panchanathan R, Shen H, Srivastava R. 2010. Interferon-inducible p200- family proteins as novel sensors of cytoplasmic DNA: role in inflammation and autoimmunity. J Interferon Cytokine Res 30(6):371-380.
16. Clemens MJ. 2003. Interferons and apoptosis. J Interferon Cytokine Res 23(6):277-292.
17. Daniel-Carmi V, Makovitzki-Avraham E, Reuven EM, Goldstein I, Zilkha N, Rotter V, Tzehoval E, Eisenbach L. 2009. The human 1-8D gene (IFITM2) is a novel p53 independent proapoptotic gene. Int J Cancer 125(12):2810-2819.
18. Dedoni S, Olianas MC, Onali P. 2010. Interferon-beta induces apoptosis in human SH-SY5Y neuroblastoma cells through activation of JAK-STAT signaling and down-regulation of PI3K/Akt pathway. J Neurochem 115(6):1421-1433.
19. Du Z, Fan M, Kim JG, Eckerle D, Lothstein L, Wei L, Pfeffer LM. 2009. Interferon-resistant Daudi cell line with a Stat2 defect is resistant to apoptosis induced by chemotherapeutic agents. J Biol Chem 284(41):27808-27815.
20. Feldman ED, Weinreich DM, Carroll NM, Burness ML, Feldman AL, Turner E, Xu H, Alexander HR Jr. 2006. Interferon gamma- inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells. Ann Surg Oncol 13(1): 125-133.
21. Fensterl V, Wetzel JL, Ramachandran S, Ogino T, Stohlman SA, Bergmann CC, Diamond MS, Virgin HW, Sen GC. 2012. Interferon- induced Ifit2/ISG54 protects mice from lethal VSV neuropathogenesis. PLoS Pathog 8(5):e1002712.
22. Folini M, Gandellini P, Longoni N, Profumo V, Callari M, Pennati M, Colecchia M, Supino R, Veneroni S, Salvioni R, Valdagni R, Daidone MG, Zaffaroni N. 2010. miR-21: an oncomir on strike in prostate cancer. Mol Cancer 9:12.
23. Fridman AL, Tainsky MA. 2008. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 27(46):5975-5987.
24. Gamero AM, Larner AC. 2001. Vanadate facilitates interferon alpha-mediated apoptosis that is dependent on the Jak/Stat pathway. J Biol Chem 276(17):13547-13553.
25. Gamero AM, Sakamoto S, Montenegro J, Larner AC. 2004. Identification of a novel conserved motif in the STAT family that is required for tyrosine phosphorylation. J Biol Chem 279(13):12379-12385.
26. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. 2011. Systemic review of medical treatment in melanoma: current status and future prospects. Oncologist 16(1):5-24.
27. Gariglio M, Mondini M, De Andrea M, Landolfo S. 2011. The multifaceted interferon-inducible p200 family proteins: from cell biology to human pathology. J Interferon Cytokine Res 31(1):159-172.
28. Gugliesi F, De Andrea M, Mondini M, Cappello P, Giovarelli M, Shoenfeld Y, Meroni P, Gariglio M, Landolfo S. 2010. The proapoptotic activity of the Interferon-inducible gene IFI16 provides new insights into its etiopathogenetic role in autoimmunity. J Autoimmun 35(2):114-123.
29. Hemmings C. 2010. The elaboration of a critical framework for understanding cancer: the cancer stem cell hypothesis. Pathology 42(2):105-112.
30. Hosono T, Tanaka T, Tanji K, Nakatani T, Kamitani T. 2010. NUB1, and interferon-inducible protein, mediates antiproliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation. Br J Cancer 102(5):873-882.
31. Huang TH, Chintalacharuvu KR, Morrison SL. 2007. Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities. J Immunol 179(10):6881-6888.
32. Itonaga H, Tsushima H, Hata T, Matsuo E, Imanishi D, Imaizumi Y, Kawaguchi Y, Fukushima T, Doi Y, Mori S, Kamihira S, Tomonaga M, Miyazaki Y. 2012. Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferonalfa. Int J Hematol 95(2):209-213.
33. Kamitani K, Kito K, Fukuda-Kamitani T, Yeh ET. 2001. Targeting of NEDD8 and its conjugates for proteasomal degradation by NUB1. J Biol Chem 276(49):46655-46660.
34. Khodarev NN, Beckett M, Labay E, Darga T, Roizman B, Weichselbaum RR. 2004. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci U S A 101(6):1714-1719.
35. Khodarev NN, Minn AJ, Efimova EV, Darga TE, Labay E, Beckett M, Mauceri HJ, Roizman B, Weichselbaum RR. 2007. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res 67(19):9214-9220.
36. Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, Shao MY, Darga TE, Beveridge MG, Sood RF, Sutton HG, Beckett MA, Mauceri HJ, Posner MC, Weichselbaum RR. 2009. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One 4(6):e5821.
37. Knowlton JJ, Dermody TS, Holm GH. 2012. Apoptosis induced by mammalian reovirus is beta interferon (IFN) independent and enhanced by IFN regulatory factor 3- and NF-kappaB-dependent expression of Noxa. J Virol 86(3): 1650-1660.
38. Kobayashi Y, Seino K, Hosonuma S, Ohara T, Itamochi H, Isonishi S, Kita T, Wada H, Kojo S, Kiguchi K. 2011. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin. Gynecol Oncol 121(2): 390-394.
39. Koike K, Takaki A, Tatsukawa M, Suzuki M, Shiraha H, Iwasaki Y, Sakaguchi K, Shiratori Y. 2006. Combination of 5-FU and IFNalpha enhances IFN signaling pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell lines. Int J Oncol 29(5):1253-1261.
40. Koldobskiy MA, Chakraborty A, Werner JK Jr, Snowman AM, Juluri KR, Vandiver MS, Kim S, Heletz S, Snyder SH. 2010. p53-mediated apoptosis requires inositol hexakisphosphate kinase-2. Proc Natl Acad Sci U S A 107(49):20947-20951.
41. Kontsek P, Karayianni-Vasconcelos G, Kontsekova E. 2003. The human interferon system: characterization and classification after discovery of novel members. Acta Virol 47(4):201-215.
42. Kudo M. 2011. Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology 81 (Suppl 1):50-55.
43. Larner AC, Chaudhuri A, Darnell Jr. J.E. 1986. Transcriptional induction by interferon. New protein(s) determine the extent and length of the induction. J Biol Chem 261(1):453-459.
44. Lasfar A, Abushahba W, Balan M, Cohen-Solal KA. 2011. Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol 2011:349575.
45. Lei H, Furlong PJ, Ra JH, Mullins D, Cantor R, Fraker DL, Spitz FR. 2005. AKT activation and response to interferon-beta in human cancer cells. Cancer Biol Ther 4(7):709-715.
46. Lengyel P. 2008. From RNase L to the multitalented p200 family proteins: an exploration of the modes of interferon action. J Interferon Cytokine Res 28(5):273-281.
47. Lindenmann J, Isaacs A. 1957. [Research on viral interference]. Schweiz Z Pathol Bakteriol 20(5):640-646.
48. Liu F, Hu X, Zimmerman M, Waller JL, Wu P, Hayes-Jordan A, Lev D, Liu K. 2011. TNFalpha cooperates with IFN-gamma to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis. PLoS One 6(1): e16241.
49. Loffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermuller J, Kretzschmar AK, Burger R, Gramatzki M, Blumert C, Bauer K, Cvijic H, Ullmann AK, Stadler PF, Horn F. 2007. Interleukin- 6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110(4):1330-1333.
50. Lokshin A, Mayotte JE, Levitt ML. 1995. Mechanism of interferon beta-induced squamous differentiation and programmed cell death in human non-small-cell lung cancer cell lines. J Natl Cancer Inst 87(3):206-212.
51. Luan Y, Lengyel P, Liu CJ. 2008. p204, a p200 family protein, as a multifunctional regulator of cell proliferation and differentiation. Cytokine Growth Factor Rev 19(5-6):357-369.
52. Ludlow LE, Purton LE, Klarmann K, Gough DJ, Hii LL, Trapani JA, Keller JR, Clarke CJ, Johnstone RW. 2008. The role of p202 in regulating hematopoietic cell proliferation and differentiation. J Interferon Cytokine Res 28(1):5-11.
53. Luszczek W, Cheriyath V, Mekhail TM, Borden EC. 2010. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. Mol Cancer Ther 9(8):2309-2321.
54. Martensen PM, Søgaard TM, Gjermandsen IM, Buttenschøn HN, Rossing AB, Bonnevie-Nielsen V, Rosada C, Simonsen JL, Justesen J. 2001. The interferon alpha induced protein ISG12 is localized to the nuclear membrane. Eur J Biochem 268(22): 5947-5954.
55. Morrison BH, Bauer JA, Hu J, Grane RW, Ozdemir AM, Chawla- Sarkar M, Gong B, Almasan A, Kalvakolanu DV, Lindner DJ. 2002. Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics. Oncogene 21(12):1882-1889.
56. Morrison BH, Bauer JA, Kalvakolanu DV, Lindner DJ. 2001. Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells. J Biol Chem 276(27):24965-24970.
57. Moserle L, Indraccolo S, Ghisi M, Frasson C, Fortunato E, Canevari S, Miotti S, Tosello V, Zamarchi R, Corradin A, Minuzzo S, Rossi E, Basso G, Amadori A. 2008. The side population of ovarian cancer cells is a primary target of IFNalpha antitumor effects. Cancer Res 68(14):5658-5668.
58. Nagano Y, Kojima Y, Sawai Y. 1954. [Immunity and interference in vaccinia; inhibition of skin infection by inactivated virus]. C R Seances Soc Biol Fil 148(7-8):750-752.
59. Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsodi J, Boll W, Cantell K, Weissmann C. 1980. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 284(5754):316-320.
60. Nagy ZS, Rui H, Stepkowski SM, Karras J, Kirken RA. 2006. A preferential role for STAT5, not constitutively active STAT3, in promoting survival of a human lymphoid tumor. J Immunol 177(8):5032-5040.
61. Nalaskowski MM, Bertsch U, Fanick W, Stockebrand MC, Schmale H, Mayr GW. 2003. Rat inositol 1,4,5-trisphosphate 3- kinase C is enzymatically specialized for basal cellular inositol trisphosphate phosphorylation and shuttles actively between nucleus and cytoplasm. J Biol Chem 278(22):19765-19776.
62. Panaretakis T, Hjortsberg L, Tamm KP, Bjorklund AC, Joseph B, Grander D. 2008. Interferon alpha induces nucleus-independent apoptosis by activating extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase downstream of phosphatidylinositol 3-kinase and mammalian target of rapamycin. Mol Biol Cell 19(1):41-50.
63. Picozzi VJ, Abrams RA, Decker PA, Traverso W, O'Reilly EM, Greeno E, Martin RC, Wilfong LS, Rothenberg ML, Posner MC, Pisters PW. 2011. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol 22(2):348-354.
64. Pokrovskaja K, Panaretakis T, Grander D. 2005. Alternative signaling pathways regulating type I interferon-induced apoptosis. J Interferon Cytokine Res 25(12):799-810.
65. Rees RC. 1990. MHC restricted and non-restricted killer lymphocytes. Blood Rev 4(3):204-210.
66. Rodriguez-Villanueva J, McDonnell TJ. 1995. Induction of apoptotic cell death in non-melanoma skin cancer by interferonalpha. Int J Cancer 61(1):110-114.
67. Romero-Weaver AL, Wang HW, Steen HC, Scarzello AJ, Hall VL, Sheikh F, Donnelly RP, Gamero AM. 2010. Resistance to IFN-alpha-induced apoptosis is linked to a loss of STAT2. Mol Cancer Res 8(1):80-92.
68. Rosebeck S, Leaman DW. 2008. Mitochondrial localization and pro-apoptotic effects of the interferon-inducible protein ISG12a. Apoptosis 13(4):562-572.
69. Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ. 2009. INTERFEROME: the database for interferon regulated genes. Nucleic Acids Res 37:D852-D857.
70. Scarzello AJ, Romero-Weaver AL, Maher SG, Veenstra TD, Zhou M, Qin A, Donnelly RP, Sheikh F, Gamero AM. 2007. A Mutation in the SH2 domain of STAT2 prolongs tyrosine phosphorylation of STAT1 and promotes type I IFN-induced apoptosis. Mol Biol Cell 18(7):2455-2462.
71. Schrama D, Reisfeld RA, Becker JC. 2006. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5(2):147-159.
72. Sgorbissa A, Tomasella A, Potu H, Manini I, Brancolini C. 2011. Type I IFNs signaling and apoptosis resistance in glioblastoma cells. Apoptosis 16(12):1229-1244.
73. Shames DS, Minna JD. 2008. IP6K2 is a client for HSP90 and a target for cancer therapeutics development. Proc Natl Acad Sci U S A 105(5):1389-1390.
74. Shen D, He J, Chang HR. 2005. In silico identification of breast cancer genes by combined multiple high throughput analyses. Int J Mol Med 15(2):205-212.
75. Stark GR, Darnell Jr. J.E. 2012. The JAK-STAT pathway at twenty. Immunity 36(4):503-514.
76. Stawowczyk M, Van Scoy S, Kumar KP, Reich NC. 2011. The interferon stimulated gene 54 promotes apoptosis. J Biol Chem 286(9):7257-7266.
77. Steen HC, Gamero AM. 2010. Interferon-lambda as a potential therapeutic agent in cancer treatment. J Interferon Cytokine Res 30(8):597-602.
78. Sun Y, Leaman DW. 2005. Involvement of Noxa in cellular apoptotic responses to interferon, double-stranded RNA, and virus infection. J Biol Chem 280(16):15561-15568.
79. Tahara E Jr, Tahara H, Kanno M, Naka K, Takeda Y, Matsuzaki T, Yamazaki R, Ishihara H, Yasui W, Barrett JC, Ide T, Tahara E. 2005. G1P3, an interferon inducible gene 6-16, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell. Cancer Immunol Immunother 54(8):729-740.
80. Thyrell L, Hjortsberg L, Arulampalam V, Panaretakis T, Uhles S, DagnellM, Zhivotovsky B, Leibiger I, Grander D,PokrovskajaK. 2004. Interferon alpha-induced apoptosis in tumor cells is mediated through thephosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J Biol Chem 279(23):24152-24162.
81. Tomokuni A, Eguchi H, Tomimaru Y, Wada H, Kawamoto K, Kobayashi S, Marubashi S, Tanemura M, Nagano H, Mori M, Doki Y. 2011. miR-146a suppresses the sensitivity to interferon- alpha in hepatocellular carcinoma cells. Biochem Biophys Res Commun 414(4):675-680.
82. Trubiani O, Bosco D, Di Primio R. 1994. Interferon-gamma (IFNgamma) induces programmed cell death in differentiated human leukemic B cell lines. Exp Cell Res 215(1):23-27.
83. Tsai MH, Cook JA, Chandramouli GV, DeGraff W, Yan H, Zhao S, Coleman CN, Mitchell JB, Chuang EY. 2007. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res 67(8):3845-3852.
84. Tsang WP, Kwok TT. 2008. Let-7a microRNA suppresses therapeutics- induced cancer cell death by targeting caspase-3. Apoptosis 13(10):1215-1222.
85. Tsuno T, Mejido J, Zhao T, Phillips T, Myers TG, Bekisz J, Zoon KC. 2012. BID is a critical factor controlling cell viability regulated by IFN-alpha. J Immunother 35(1):23-31.
86. Vilcek J. 2003. Novel interferons. Nat Immunol 4(1):8-9.
87. Wellbrock C, Weisser C, Hassel JC, Fischer P, Becker J, Vetter CS, Behrmann I, Kortylewski M, Heinrich PC, Schartl M. 2005. STAT5 contributes to interferon resistance of melanoma cells. Curr Biol 15(18):1629-1639.
88. Xuan C, Steward KK, Timmerman JM, Morrison SL. 2010. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 115(14):2864-2871.
89. Yang CH, Murti A, Pfeffer LM. 2005. Interferon induces NF-kappa B-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation to promote cell survival. J Biol Chem 280(36):31530-31536.
90. Yang CH, Murti A, Pfeffer SR, Basu L, Kim JG, Pfeffer LM. 2000. IFNalpha/beta promotes cell survival by activating NF-kappa B. Proc Natl Acad Sci U S A 97(25):13631-13636.
91. Yang CH, Yue J, Fan M, Pfeffer LM. 2010. IFN induces miR-21 through a signal transducer and activator of transcription 3- dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res 70(20):8108-8116.
92. Yoshino A, Tashiro S, Ogino A, Yachi K, Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Sano E, Tsumoto K. 2011. Gene expression profiles predicting the response to IFNbeta and a combination of temozolomide and IFN-beta in malignant gliomas. Int J Oncol 39(3):529-542.
93. Young CW. 1971. Interferon induction in cancer: with some observations on the clinical aspects of poly 1:c. Med Clin North Am 55(3):721-728.
94. Yue C, Soboloff J, Gamero AM. 2012. Control of type I interferon- induced cell death by Orai1-mediated calcium entry in T cells. J Biol Chem 287(5):3207-3216.
95. Zhang R, Banik NL, Ray SK. 2007. Combination of all-trans retinoic acid and interferon-gamma suppressed PI3K/Akt survival pathway in glioblastoma T98G cells whereas NF-kappaB survival signaling in glioblastoma U87MG cells for induction of apoptosis. Neurochem Res 32(12):2194-2202.
96. Zhang T, Sun HC, Zhou HY, Luo JT, Zhang BL, Wang P, Wang L, Qin LX, Ren N, Ye SL, Li Q, Tang ZY. 2010. Interferon alpha inhibits hepatocellular carcinoma growth through inducing apoptosis and interfering with adhesion of tumor endothelial cells. Cancer Lett 290(2):204-210.